Iconovo develops drug inhalation products, offering exposure to the growing market for inhaled generics in the treatment of asthma and COPD.
It has managed to sign three royalty agreements with global generic drug companies. Iconovo focuses on early-stage out-licensing of projects, reducing risk in the business model. The licensing partner takes clinical and commercial risk, while Iconovo retains the option of royalty revenues. Read more